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The Kaplan-Meier survival curve is one of the most frequently used statistical methods to analyze the probability of disease free over a period of time.​[2]​,​[3]​ In disease free survival curves, the event of interest is relapse of a disease.​[4]​ 
There are three assumptions used in this analysis.  First, at any time patients who are censored have the same survival prospects as those who continue to be followed;  second, the survival probabilities are the same for subjects recruited early and late in the study;  third, the event happens at the time specified.​[5]​ This study satisfies these assumptions.





Table S1. 	The durations of the treatments and the post-treatments in the clinical studies reviewed by the American College of Gastroenterology for its recommendations
Therapies Recommendation	# of RCT4; # of patients.	Durations of each studies (Treatment + Post-treatment)
 Exercise Recommendation: weak	2 RCTs (38,39); 158 patients. 	12W+0; 12W+0.
Diet & dietary manipulation	 Low FODMAP diet
 Recommendation: weak	7 RCTs (43–49); 397 patients.	4W+0; 4W+0; 3W+0; 4W+7D, 4W+4W5; 3W+0; *** (a cross-over study). 
	 Gluten-free diet1
 Recommendation: weak	2 RCTs (54, 55); 111 patients.	6W+0; 6W+0. 
 Fiber
 Recommendation: strong	15 RCTs (58–72); 946 patients.	6W+0; 6W+0; 4W+0; 8W+0; 4W+0; no info; 16W+0; 3M+0; 12W+0; 4W+0; 3M+0; 12W+0; 12W+0; 4W+0; 4W+0. 
 Prebiotics1
 Recommendation: weak	1 RCT (80); 128 patients.	8W+0.
 Synbiotics1
 Recommendation: weak	2 RCTs (81, 82); 198 patients.	12W+0; 8W+0.
 Probiotics
 Recommendation: weak	37 RCTs (47, 84, 86–89, 91, 92, 94-104, 110, 112, 113,  115, 118, 119, 121, 123, 125-134);  4403 patients.	4W+0; 8W+2W5; 12W+0; 4W+0; 6W+0; 4W+0; 6W+0; 8W+3W; 4W+0; 8W+8W; 12W+0; 8W+0; 10W+0; 12W+0; 4W+0; 4W+12M; 4W+0; 10W+0; 6M+0; 4W+0; 4W+0; 8W+0; 4W+0; 8W+0; 8W+0; 8W+0; 4W+0; 8W+0; 8W+0; 10W+0; 4W+0; 4W+0; 4W+0; *** (two 3-week tx separated by 4 washout); 12W+0; 6M+6M; 12W+0. 
 Antibiotics (rifaximin)
 Recommendation: weak	6 RCTs (137, 139–142);  2441 patients.	2W+10W6; 30D+0; 10D+10W; ***7; 2W+10W (TARGET 1) / 3M (TARGET 2).
 Antispasmodics 
 Recommendation: weak	26 RCTs (60, 63, 64, 149– 171); 2811 patients.	4W+0; no info; 16W+0; 4W+0; 4W+0; ***7; 4W+0; 6M+0; 3M+0; 1M+0; 4W+0; 2W+0, 1W+0; 6M+0; 60D+0; 4W (and then crossed over)+0; no info; 15W+0; 4W+0; 12W+0; 6W+0; 2W+0; 4W+0; ***8; 4W+0; 15W+10W.
 Peppermint oil	7 RCTs (172–178); 634 patients.	4W+0; 4W+2W; 4W+0; 1M+0; 4W+4W; 3M+0; 8W+0. 
Antidepressants 	 TCAs
 Recommendation: strong	12 RCTs (63, 188–194, 197, 200, 201, 204); 787 patients.	no info; 10W+0; 2M+0; 4W+0; 8W+0; 3M+0; 6W+0; 12W+0; 2M+0; 12W+0; 12W+0; 2M+0. 
	 SSRIs 
 Recommendation: weak	7 RCTs (195, 196, 198–200,   202, 203); 356 patients.	6W+0; 7W+0; 12W+4W; 6W+0; 12W+0; 12W+0; 8W+0. 
 Psychological therapies	36 RCTs (published in 34 articles: 194, 211–243); 2487 patients.	12W+0; 8W+0; 12M+0; 8W+3M; 2W+3M; 8W+0; 8W+0; 6W+3M; 1M+5M; 12M+0; 8W+0; 12W+0; *** (a crossover study); 12W+3M; 12W+1Y; 8W+2Y (no Control -- compared with baseline); 8W (Comprehensive tx) / 1D (Brief tx)+12M; 8W+0; 8W+0; 7W+6M; 5W+3M; 10W+3M; 6M+0; 3M+1Y; 8W+6M; 8W+3M; 2M+0; 10W+0; 10W+0; 10W+2W; 9W+1Y; 8W+1Y9; 8W+0; 3W+10W.
Prosecretory agents	 Linaclotide2
 Recommendation: strong	4 RCTs (245–248); 2867 patients.	12W+0; 12W+0; 26W+0; *** (a crossover clinical trial). 
	 Plecanatide2
 Recommendation: strong	3 RCTs (2 RCTs published in 249, 1 published in 250); 2612 patients.	12W+0; 12W+0.
	 Lubiprostone2
 Recommendation: strong	3 RCTs (3 RCTs published   in 254 and 255); 1366 patients.	12W+0, 3M+0.
 Eluxadoline3
 Recommendation: weak	3 RCT (3 RCTs published in 257 and 258); 3235 patients.	52W+0; 12W+0.
 Loperamide1
 Recommendation: strong	2 RCTs (259, 260); 42 patients.	3W+0; 13W+0.
 Alosetron3
 Recommendation: weak	8 RCTs (265–272); 4987 patients.	12W+0; 12W+4W; 12W+4W; 12W+0; 12W+2W; 48W+4W; 12W+4W; 12W+0. 
 Polyethylene glycol1	2 RCTs (274,275); 181 patients. 	30D+0, 4W+0.
 5-aminosalicylates1
 Recommendation: weak	3 RCTs (281–283); 464 patients.	12W+12W; 12W+0; 12W+0.
This table is the summary of Ford et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113 (Suppl 2):1-18.
Note: 1: not recommended. 2. recommended in IBS-C patients. 3: recommended in IBS-D patients. 4: the reference numbers in this column refer to the references cited by Ford et al. 2018. 5: 2 X 2 factorial trial, not comparing a single treatment with a placebo/control. 6: Repeated treatment design: 2 weeks of first rifaximin treatment + 10 weeks follow-up + 2 weeks of second rifaximin treatment + 4 weeks follow-up. Data from the first treatment and the first follow-up were used here. 7: preliminary results as an Abstract only. 8: this study (Ref. 169, Castiglione et al. 1991) is a review article, not an original research article. 9: this study (Boyce at al. 2003) did not compare a psychological therapy alone with a treatment as usual; this study compared three arms (a. cognitive behavior therapy plus standard care therapy, b. relaxation therapy plus standard care therapy, and c. standard care therapy). This design could not single out the effects of either behavior therapy.   
Abbreviation: D = days; M = months; Y = year; no info = no information; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; tx = treatment; W = weeks. 







Table S2.  Studies on post-treatment therapeutic effects.
Trail #	Trails	Study design	 S / M-sites?1	# of pt (ITT)	Treatment	Post-treatment
				Tx group	Placebo (Control) group	Tx	Tx Duration	Date collected at	Outcome endpoints	FDA endpnts?2	Tx effective?	Post-tx follow-up duration	Date collected at	+ therapeutic effect?3	+ PTTE duration	Entire PTTE?4	Know + PTTE duration?5	IBS natural history?6	Studied relapse-free probability?	Pt # (%) stayed relapse-free
1	Staudacher et al. 2012.​[6]​	randomized, controlled	S	19	22 (habitual diet)	Low FODMAP diet	4 wk	wk 1	bloating, pain, flatulence, borborygmus, urgency, diarrhea, constipation, incomplete evacuation, heartburn, nausea, lethargy.	N	Y	1 wk	wk 1	Y	≥ 1 wk	N	N	N	N	N
2	Pineton et al. 2015.​[7]​	double-blind, randomized, placebo-controlled	S	86	93	S. cerevisiae	8 wk	every wk.	pain / discomfort; bloating/distension, bowel movement difficulty, stool frequency and consistency.	N	Y	3 wk	every wk.	Y	1-2 wk	Y	Y	1 wk (but not adequate)	N	N
3	Nobaek et al. 2000.​[8]​	double-blind, randomized, placebo-controlled	S	30	30	L. plantarum	4 wk	every wk	defecation #, fecal consistency, abundant gas, overall GI function, defecation function, pain, and flatulence.	N	Y	12 mo	mo 12	Y	≥ 12 mo	N	N	N	N	N
4	Begtrup et al. 2013.​[9]​	double-blind, randomized, placebo-controlled	S	67	64	probiotics	6 mo	every mo	pt % of relief; GI symptom changes, QoL. 	N	N	6 mo	every mo	N/A	N/A	N/A	N/A	N/A	N/A	N/A
5	Lembo et al. 2016.​[10]​	double-blind, randomized, placebo-controlled	M	328	308	 rifaximin	2 wk7	every wk	responding % to pain, to loose stool frequency; urgency, global IBS symptoms.	N	Y	10 wk7	every wk	Y	≥ 10 wk	N	N	N	N	N
6	Pimentel et al. 2006.​[11]​	double-blind, randomized, placebo-controlled	M	43	44	 rifaximin	10 days	wk 0,1	pain, diarrhea, constipation, bloating, urgency, incomplete evacuation, mucus, gas.	N	Y	10 wk	every wk	Y	≥ 10 wk	N	N	N	N	N
7	Pimentel et al. 2011.​[12]​	double-blind, randomized, placebo-controlled	M	309 / 316	314 / 321	 rifaximin	2 wk	every wk	pt % of relief of global symptoms; pt % of relief of bloating; pt % of global symptoms, bloating, pain, and stool consistency.	N	Y	3 mo	every wk	Y	≥ 3 mo.	N	N	N	N	N
				TARGET 1 / TARGET 2															
8	Clavé et al. 2011.​[13]​	double-blind, randomized, placebo-controlled	M	179	177	otilonium	15 wk	wk 0, 5, 10, 15.	pain frequency; pt global assess, MD  global assess, pain, bloating-meteorism, stool consistency / frequency, mucus; QoL; response rates.	N	Y	10 wk	wk 3,6,10.	Y	 ≥ 10 wk	N	N	N	Y	N


40 pepper-mint oil.	 anise oil 	4 wk	wk 0, 4	pain, discomfort, bloating, diarrhea, constipation severity, difficulty in defecation, GI reflux, headache, tiredness, overall satisfaction; QoL.	N	Y	2 wk	wk 2	Y	≥ 2 wk	N	N	N	N	N
10	Cappello et al. 2007.​[14]​	double-blind, randomized, placebo-controlled	S	28	29	peppermint oil	4 wk	wk 0, 4	bloating, pain/discomfort, diarrhoea, constipation, incomplete evacuation, gas or mucus and urgency at defecation.	N	Y	4 wk	wk 4	Y	≥ 4 wk	N	N	N	N	N
11	Vahedi et al. 2005.​[15]​	double-blind, randomized, placebo-controlled	S	22	22	fluoxetine	12 wk	every 2 wk	discomfort, bloating, stool consistency, bowel movement frequency, bowel habit	N	Y	4 wk	wk 4	Y	≥ 4 wk	N	N	N	N	N
12	Payne & Blanchard. 1995.​[16]​	randomized, controlled	S	12	10 WLC;
12 self-help support	cognitive-based tx	8 wk	wk 0, 8	pain, tenderness, constipation, diarrhea, flatulence, belching, bloating; BDI, STAI; DAS, ATQ.	N	Y	3 mo	mo 3	Y	≥ 3 mo	N	N	N	N	N
13	Tkachuk et al. 2003.​[17]​	randomized, controlled	M	14	14 home-based symptom monitor	cognitive-behavioral group therapy	9 wk	every wk	IBS symptoms (abdominal pain, diarrhea, constipation, bloating, flatulence, and nausea), psychological functioning, QoL.	N	Y	3 mo	mo 3	Y	≥ 3 mo	N	N	N	N	N
14	Keefer et al. 2001.​[18]​	randomized, controlled	S	8	8 WLC	relaxation response meditation	6 wk	wk 0	primary IBS symptom reduction	N	Y	3 mo	wk 2, mo 3	Y	≥ 3 mo	N	N	N	N	N
15	Lynch and Zamble. 1989.​[19]​	randomized, controlled	S	11	10 WLC	behavioral treatment	8 wk	before and after the tx	pain, disomfort, stool consistency, mucus, bloating, flatulence, belching, nausea, insomnia, anxiety, QoL, bowel movements, analgestics usage, psychotropics usage.	N	Y	5 mo	mo 5	Y	≥ 5 mo	N	N	N	N	N
16	Lindfors et al. 2012.​[20]​	randomized, controlled	M	45 / 25	45 support therapy / 23 WLC	hypnotherapy	12 wk	wk 0	bloating, gas, pain, loose stools, urgency, hard stools, and incomplete evacuation, QoL.	N	Y	1 yr	mo 3, yr 1	Y	≥ 1 yr	N	N	N	N	N
				Study 1 / Study 2															
17	Heitkemper et al. 2004​[21]​	randomized, controlled	S	Comp: 40
Brief: 48	44 TAU 	Comp: 
8 wkly 1 hr
Brief: 
one 90 min	Comp: 8 wk
Brief: 1 day	wk 0	pain, bloating, gas, constipation, diarrhea, QoL, SCL-90R, GSI, CSBD.	N	Y	12 mo	wk 9, mo 6, 12	Y	≥ 1 yr	N	N	N	N	N
18	Moss-Morris et al. 2010.​[22]​	randomized, controlled	S	31 (CBT + TAU) 	33 TAU	cognitive behavioral therapy	7 wk	wk 0	global assessment, IBS Syndrome Scoring System.	N	Y	6 mo	mo 2, 3, 6	Y	≥ 6 mo	N	N	N	N	N
19	Hunt et al. 2009.​[23]​	randomized, controlled	via internet	28	26 WLC	cognitive-behavioral internet therapy 	5 wk	wk 0	bloating, diarrhea, constipation, pain, satiety; Anxiety Sensitivity Index; Visceral anxiety sensitivity; QoL; Consequences of Physical Sensations Questionnaire.	N	Y	3 mo	wk 6, mo 3	Y	≥ 3 mo	N	N	N	N	N
20	Ljotsson et al. 2010.​[24]​	randomized, controlled	via internet	43	43 WLC	cognitive behavioral therapy	10 wk	every wk	pain, tenderness, diarrhea, constipation, bloating, flatulence, belching and nausea; QoL, GI-specific anxiety, depression, functioning.	N	Y	3 mo	wk 1, 2, 3, mo 3	Y	≥ 3 mo	N	N	N	N	N
21	Creed et al. 2003​[25]​	single-blind, randomized, controlled	M	85psycho-therapy; 
86paroxt-ine. 	86 tx as usual	Group 1: psycho-therapy;
Group 2: paroxetine 20 mg, QD 	3 mo 	mo 0, 3	pain, # of days with pain, overall symptoms.	N	Y	1 yr	yr 1	no conclusion 
due to low DCR	< 1 yr (very low DCR)	Y	N	Y	N	N
22	Zernicke et al. 2013.​[26]​	randomized, controlled	S	43	47 WLC	mindfulness-based stress reduction	8 wk	wk 0, 8	pain, pain frequency, distension, bowel habit dissatisfaction, and life interference; QoL; stress, mood, and spirituality scales.	N	Y	6 mo	mo 6	Y	< 6 mo  (low DCR)	Y	N	N	N	N
23	Gaylord et al. 2011.​[27]​	randomized, controlled	S	36	39 social-support	mindfulness-based stress and pain management	8 wk	wk 0	IBS severity scale; QoL, visceral sensitivity index, brief symptom inventory-18.	N	Y	3 mo	after tx, mo 3.	Y	≥ 3 mo	N	N	N	N	N
24	Lackner et al. 2008.​[28]​	randomized, controlled	S	25 pt CBT8: 
23 tpt CBT8: 	27 WLC	cognitive behavior therapy	10 wk	wk 0.	relief (pain, bowel symptoms); global symptoms; symptom scale; QoL; psychological distress; pt satisfaction scale.	N	Y	2 wk	wk 2	Y	≥ 2 wk	N	N	N	N	N
25	Jarrett et al. 2009.​[29]​	randomized, controlled	S	CSM i/p: 58;
t,i/p: 58	60 TAU	comp self-management (CSM) 	9 wk	wk 0.	pain, discomfort, bloating, constipation, diarrhea, intestinal gas, urgency, QoL; psychological distress sales. 	N	Y	1 yr	 mo 3, 6, 12. 	Y	≥ 1 yr	N	N	N	Y	N
26	Camilleri et al. 2000.​[30]​	randomized, placebo-controlled	M	324	323	alosetron, 
1 mg, BID	12 wk	every wk	relief of pain and discomfort; urgency, stool frequency, stool consistency. 	N	Y	4 wk	every wk	N	< 1 wk	Y	Y	Y (but not adequate)	N	N
27	Camilleri et al. 2001.​[31]​	double-blind, randomized, placebo-controlled	M	309	317	alosetron, 
1 mg, BID	12 wk	every wk	relief of pain and discomfort; urgency, stool frequency, stool consistency, incomplete evacuation, and bloating.	N	Y	4 wk	every wk	N	< 1 wk	Y	Y	Y (but not adequate)	N	N
alosetron, 
1 mg, BID	12 wk	every wk	day % of satisfactory bowel urgency; global symptoms, stool frequency / consistency, incomplete evacuation.	N	Y	2 wk	every wk	N	< 1 wk	Y	Y	N	N	N
29	Chey et al. 2004.​[32]​	double-blind, randomized, placebo-controlled	S	351	363	alosetron, 
1 mg, BID	12 mo	every mo	relief of pain and discomfort; urgency, stool frequency, stool consistency, and bloating.	N	Y	1 mo	mo 1	N	< 1 mo	Y	Y	N	N	N
30	Chang et al. 2005.​[33]​	randomized, double blind, placebo-controlled 	M	127/131/136/ 140 (.5/1/2/4 mg)	128	alosetron 0.5, 1.0, 2.0, 4.0 mg, BID	12 wk	every wk for wk 5 -12	adequate relief of pain, discomfort; bowel urgency, stool frequency, stool consistency,
incomplete evacuation, bloating.	N	Y only for 1 mg	4 wk	every wk	N	< 1 wk	Y	Y	N	N	N
31	Barbara et al. 2016.​[34]​	double-blind, randomized, placebo-controlled	M	88	92	mesalazine, 
800 mg, TID	12 wk	every wk	relief of pain/discomfort; overall symptoms, bloating, general well-being, stool frequency / consistency, QoL.	N	N	12 wk	every 4 wk	N/A	N/A	N/A	N/A	N/A	N/A	N/A
32	Henrich et al. 2020.​[35]​	randomized, controlled	S	36	31 WLC	mindfulness-based cognitive therapy	6 wk	wk 0,6	IBS symptom severity, IBS quality of life, maladaptive catastrophizing, visceral anxiety sensitivity, mindfulness. 	N	Y	6 wk	wk 6	Y	≥ 6 wk	N	N	N	N	N
33	Shin et al. 2020.​[36]​	double-blind, randomized, placebo-controlled	S	36	36	phloroglucinol	2 wk	wk 0,2	pain/discomfort, loose/watery stool, urgency, mucus, bloating, gas; QoL. 	N	Y	1 wk	wk 1	Y	≥ 1 wk	N	N	N	N	N
34	Everitt et al. 2019.​[37]​	randomized, controlled	M	TCBT: 186;
WCBT: 185	187 TAU	telephone CBT (TCBT);
web CBT (WCBT)	8 mo	mo 0,3,6	pain, distension/tightness, bowel habit, QoL; Hospital Anxiety and Depression Scale.	N	Y	4 mo	mo 4	Y	≥ 4 mo	N	N	N	N	N

Note: Regular font: the trials reviewed by Ford et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113 (Suppl 2):1-18. Italic font: updated studies not reviewed by the American College of Gastroenterology.		
1: 	Single (S) or multi (M) centers? Unless it was said to be of multi-center, single-center is assumed here. 		
2: 	Did the study use FDA recommended endpoints? US Food and Drug Administration. Guidance for industry irritable bowel syndrome — clinical evaluation of drugs for treatment. Final Guidance. Silver Springs, MD: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 2012.		
3: 	Were there positive post-tx therapeutic effects? As long as at either pain or stool outcome endpoint remained positive post-treatment therapeutic effects, the treatment was considered to have a positive post-treatment effect. 		
4: 	Was the post-tx follow-up long enough to reach the end of the extended + therapeutic effects during the post-treatment period?		
5: 	Was the post-tx follow-up long enough and data collection resolution high enough to draw a conclusion on how long + therapeutic effects could last?		
6: 	Was the post-tx follow-up long enough to cover both the + therapeutic effects period and IBS natural history?		
7: 	Repeated treatment design: 2 wk of first rifaximin treatment + 10 wk follow-up + 2 wk of second rifaximin treatment + 4 wk follow-up. Data from the first treatment and the first follow-up were used here.   		
8: 	pt CBT = patient administered CBT or minimal contact CBT; tpt CBT = therapist administered CBT or standard CBT. 		











Table S3.  Irritable Bowel Syndrome (IBS-D) questionnaire
	Patient ID:                .
Name:                             Gander:  M    F  Age            Phone                                                       .                                                  
Address                                                                        ZIP             . Others                                      .     
Treatment history of IBS:How long have you suffered the symptoms of IBS-D? ______ years and ______months.   Have you ever received treatment?      Yes (go to next Question);       No (go to Question 6)Name of the drug(s) used for IBS? ___________________________________________________________________________Are you still taking the drugs in Question 3?  Yes  Stop. Need 10 days of drug free No  How long stop the drug(s)?__________Reasons of stopping the drugs: 	 Effective, but IBS recurs later;       Effective due to side effects;  Effective but the drugs are expensive;    Somewhat effective, not completely relieve the symptoms;    Not effective;          Others                                                                                                           .                            

Diagnostic Criteria of IBS (symptom onset at least 6 months prior to diagnosis, and in the last 3 months associated with two or more in 7):How many months do you have recurrent abdominal pain on average at least 1 day/week? (Inclusion criteria: in the last 3 months) Related to defecation;  Associated with a change in the frequency of stool;   Associated with a change in the form (appearance) of stool (Inclusion criteria: two or more of the above)
Table S4.  The bowel symptom scale questionnaire   

























 Table S5.  The mean (95% confidence interval) of the primary and secondary endpoints (ITT) 
 	Pinaverium	 	Placebo	 
	Primary endpoints		Secondary endpoints		Primary endpoints		Secondary endpoints	




Baseline	4.92 (4.67–5.18)		6.10 (5.96–6.24)		4.66 (4.40–4.92)		4.36 (4.17–4.54)		5.03 (4.75–5.31)		6.01 (5.96–6.24)		4.56 (4.30–4.82)		4.15 (3.97–4.34)	

Day 1	3.51 (3.27–3.74)		5.14 (4.92–5.35)		3.28 (3.05–3.51)		3.50 (3.31–3.69)		4.35 (4.11–4.58)		5.53 (4.92–5.35)		4.05 (3.81–4.28)		3.72 (3.54–3.90)	

Day 2	3.52 (3.25–3.78)		5.08 (4.89–5.27)		3.30 (3.07–3.54)		3.26 (3.08–3.44)		4.24 (4.01–4.48)		5.47 (4.89–5.27)		3.89 (3.66–4.13)		3.60 (3.42–3.77)	

Day 3	3.20 (2.93–3.47)		4.77 (4.56–4.97)		2.95 (2.71–3.20)		2.91 (2.72–3.10)		4.12 (3.88–4.37)		5.45 (4.56–4.97)		4.02 (3.77–4.27)		3.35 (3.18–3.52)	

Week 1	3.23 (2.95–3.52)		4.58 (4.35–4.80)		3.00 (2.75–3.25)		2.73 (2.52–2.95)		4.21 (3.95–4.47)		5.22 (4.35–4.80)		3.92 (3.66–4.19)		3.05 (2.85–3.24)	





Day 1	3.52 (3.19–3.85)		4.39 (4.14–4.65)		3.11 (2.83–3.39)		2.52 (2.34–2.69)		4.24 (3.99–4.50)		5.02 (4.14–4.65)		3.75 (3.50–4.00)		2.99 (2.82–3.16)	

Day 2	3.52 (3.17–3.86)		4.49 (4.25–4.73)		3.04 (2.75–3.33)		2.66 (2.46–2.86)		4.37 (4.09–4.65)		5.25 (4.25–4.73)		3.75 (3.52–3.98)		2.94 (2.76–3.11)	

Day 3	3.63 (3.28–3.98)		4.74 (4.49–4.99)		3.12 (2.82–3.42)		2.92 (2.72–3.13)		4.18 (3.92–4.45)		5.20 (4.49–4.99)		3.82 (3.55–4.08)		3.24 (3.06–3.42)	

Week 4	3.77 (3.41–4.12)		4.85 (4.60–5.09)		3.45 (3.13–3.78)		3.02 (2.82–3.23)		4.39 (4.09–4.70)		5.27 (4.60–5.09)		3.94 (3.69–4.19)		3.52 (3.34–3.71)	

Week 9	3.92 (3.57–4.27)		4.88 (4.64–5.12)		3.53 (3.22–3.84)		3.23 (3.03–3.43)		4.44 (4.14–4.74)		5.24 (4.64–5.12)		3.98 (3.70–4.27)		3.61 (3.40–3.83)	

Week 17	4.00 (3.64–4.36)		4.77 (4.52–5.03)		3.92 (3.56–4.27)		3.22 (3.01–3.43)		4.32 (4.03–4.60)		5.07 (4.52–5.03)		4.12 (3.83–4.41)		3.46 (3.25–3.68)	

Week 25	4.46 (4.06–4.87)		5.00 (4.76–5.24)		3.66 (3.35–3.97)		3.40 (3.21–3.60)		4.44 (4.11–4.77)		5.02 (4.76–5.24)		4.01 (3.72–4.30)		3.52 (3.30–3.73)	

Week 33	4.63 (4.23–5.03)		5.08 (4.83–5.32)		3.79 (3.48–4.09)		3.55 (3.33–3.76)		4.47 (4.14–4.80)		5.26 (4.83–5.32)		3.99 (3.70–4.29)		3.41 (3.17–3.65)	

Week 45	4.58 (4.16–5.01)		4.95 (4.69–5.21)		3.90 (3.56–4.24)		3.32 (3.13–3.51)		4.14 (3.82–4.46)		5.21 (4.69–5.21)		4.20 (3.90–4.50)		3.57 (3.34–3.80)	
 
Week 57	4.50 (4.08–4.92)		5.33 (5.06–5.59)		4.00 (3.65–4.35)		3.62 (3.41–3.83)		4.63 (4.30–4.95)		5.05 (5.06–5.59)		3.91 (3.61–4.21)		3.37 (3.15–3.59)	
 
Abbreviations: freq. = frequency; Stool consist. = Stool consistency. 
 
Table S6.  The mean and 95% confidence interval (CI) of the primary and secondary endpoints (PP) 
 	Pinaverium	 	Placebo	 
	Primary endpoints		Secondary endpoints		Primary endpoints		Secondary endpoints	




Baseline	5.01 (4.71–5.32)		6.09 (5.92–6.25)		4.79 (4.49–5.09)		4.40 (4.19–4.61)		5.14 (4.80–5.48)		6.00 (5.84–6.16)		4.70 (4.38–5.02)		4.17 (3.93–4.41)	

Day 1	3.61 (3.32–3.90)		5.12 (4.87–5.37)		3.42 (3.16–3.69)		3.50 (3.28–3.72)		4.46 (4.18–4.74)		5.62 (5.44–5.80)		4.09 (3.82–4.36)		3.66 (3.46–3.85)	

Day 2	3.66 (3.35–3.98)		5.11 (4.89–5.33)		3.39 (3.11–3.67)		3.25 (3.05–3.45)		4.21 (3.91–4.50)		5.49 (5.31–5.68)		3.98 (3.69–4.26)		3.53 (3.32–3.73)	

Day 3	3.27 (2.95–3.60)		4.76 (4.52–5.00)		3.12 (2.82–3.42)		2.98 (2.76–3.20)		4.21 (3.90–4.21)		5.48 (5.29–5.68)		4.09 (3.78–4.41)		3.33 (3.12–3.33)	

Week 1	3.32 (2.98–3.66)		4.54 (4.28–4.81)		3.11 (2.81–3.40)		2.62 (2.37–2.87)		4.29 (3.96–4.62)		5.30 (5.04–5.56)		3.93 (3.60–4.27)		3.08 (2.84–3.08)	





Day 1	3.62 (3.27–3.97)		4.46 (4.15–4.77)		3.16 (2.86–3.47)		2.51 (2.31–2.71)		4.28 (3.95–4.60)		5.08 (4.80–5.36)		3.75 (3.44–4.05)		2.95 (2.75–3.16)	

Day 2	3.57 (3.16–3.98)		4.52 (4.23–4.81)		3.12 (2.78–3.46)		2.59 (2.35–2.82)		4.44 (4.09–4.79)		5.24 (5.00–5.48)		3.75 (3.47–4.02)		2.91 (2.69–3.12)	

Day 3	3.71 (3.28–4.14)		4.77 (4.47–5.07)		3.12 (2.76–3.48)		2.86 (2.61–3.11)		4.28 (3.96–4.60)		5.22 (4.94–5.49)		3.84 (3.51–4.17)		3.17 (2.95–3.40)	

Week 4	3.86 (3.44–4.28)		4.93 (4.65–5.22)		3.49 (3.11–3.86)		2.98 (2.74–3.22)		4.49 (4.11–4.88)		5.28 (4.99–5.56)		4.01 (3.70–4.32)		3.44 (3.20–3.67)	

Week 9	3.96 (3.54–4.37)		4.89 (4.60–5.18)		3.63 (3.25–4.01)		3.28 (3.05–3.51)		4.49 (4.11–4.49)		5.31 (5.04–5.58)		4.03 (3.68–4.39)		3.56 (3.30–3.83)	

Week 17	3.97 (3.55–4.39)		4.85 (4.55–5.15)		3.98 (3.54–4.41)		3.15 (2.90–3.40)		4.39 (4.05–4.73)		5.13 (4.83–5.42)		4.10 (3.75–4.46)		3.48 (3.21–7.75)	

Week 25	4.51 (4.50–4.97)		4.97 (4.69–5.25)		3.73 (3.37–4.09)		3.33 (3.09–3.56)		4.52 (4.11–4.92)		5.05 (4.76–5.33)		4.02 (3.65–4.40)		3.47 (3.19–3.76)	

Week 33	4.64 (4.17–5.11)		5.13 (4.83–5.43)		3.84 (3.49–4.18)		3.47 (3.21–3.73)		4.55 (4.16–4.95)		5.24 (4.93–5.55)		4.02 (3.65–4.39)		3.37 (3.05–3.37)	

Week 45	4.66 (4.16–5.16)		4.95 (4.63–5.26)		4.02 (3.62–4.43)		3.38 (3.14–4.62)		4.20 (3.82–4.57)		5.17 (4.88–5.46)		4.30 (3.95–4.65)		3.55 (3.26–3.84)	

Week 57	4.55 (4.07–5.04)		5.33 (5.01–5.65)		4.13 (3.72–4.54)		3.62 (3.38–3.86)		4.67 (4.27–5.07)		5.00 (4.69–5.31)		4.00 (3.64–4.36)		3.24 (2.96–3.52)	
 









Table S7.	  The relative risk (RR) and 95% confidence interval (CI) in patients who suffered moderate or severe IBS symptoms (ITT)
 	Primary endpoints		Secondary endpoints	 
	Pain 		Stool consistency		Pain freq.		Stool freq.	
	RR	95% Cl	P		RR	95% Cl	P		RR	95% Cl	P		RR	95% Cl	P	
Treatment

Day 1	0.74	0.66	–	0.83	< .001		0.82	0.72	–	0.93	< .005		0.78	0.69	–	0.89	< .001		0.91	0.83	–	0.99	< .05	

Day 2	0.74	0.65	–	0.84	< .001		0.81	0.70	–	0.92	< .005		0.75	0.65	–	0.87	< .001		0.89	0.80	–	0.99	< .05	

Day 3	0.70	0.61	–	0.81	< .001		0.74	0.63	–	0.86	< .001		0.65	0.55	–	0.76	< .001		0.80	0.70	–	0.92	< .001	

Week 1	0.70	0.60	–	0.81	< .001		0.73	0.60	–	0.89	< .005		0.79	0.67	–	0.91	< .005		0.81	0.68	–	0.97	< .05	





Day 1	0.71	0.61	–	0.81	< .001		0.60	0.48	–	0.76	< .001		0.75	0.64	–	0.88	< .001		0.71	0.58	–	0.87	< .001	

Day 2	0.68	0.59	–	0.79	< .001		0.61	0.48	–	0.76	< .001		0.71	0.61	–	0.83	< .001		0.77	0.63	–	0.94	< .010	

Day 3	0.75	0.65	–	0.87	< .001		0.66	0.53	–	0.82	< .001		0.75	0.64	–	0.88	< .001		0.83	0.71	–	0.96	< .05	

Week 4	0.84	0.73	–	0.97	< .05		0.80	0.66	–	0.98	< .05		0.79	0.68	–	0.91	< .005		0.84	0.73	–	0.98	< .05	

Week 9	0.84	0.73	–	0.97	< .05		0.80	0.64	–	0.99	< .05		0.86	0.74	–	0.99	< .05		0.84	0.72	–	0.99	< .05	

Week 17	0.90	0.78	–	1.03	> .05		0.83	0.68	–	1.02	> .05		0.89	0.77	–	1.02	> .05		0.97	0.83	–	1.13	> .05	

Week 25	0.89	0.78	–	1.01	> .05		0.86	0.71	–	1.05	> .05		0.93	0.81	–	1.07	> .05		1.01	0.88	–	1.16	> .05	

Week 33	0.92	0.81	–	1.04	> .05		0.85	0.70	–	1.02	> .05		0.95	0.83	–	1.09	> .05		1.04	0.90	–	1.20	> .05	

Week 45	0.92	0.80	–	1.04	> .05		0.84	0.69	–	1.02	> .05		0.96	0.84	–	1.10	> .05		1.02	0.89	–	1.17	> .05	

Week 57	0.95	0.84	–	1.08	> .05		0.91	0.75	–	1.10	> .05		0.98	0.85	–	1.13	> .05		1.11	0.96	–	1.27	> .05	





Table S8.	Average Inter-item Correlation (r∑) analysis of the primary and secondary endpoints during / post- treatment (ITT)
Treatment
Day 1	Pain	 	 	Pain freq	 	 	Stool consist	 
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.438	< 0.01							
Stool consistency	0.291	< 0.01		0.285	< 0.01				
Stool frequency	0.176	< 0.1		0.024	> 0.1		0.212	< 0.02	
Average Inter-item Correlation = 	0.238	< 0.01	
Day 2	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.551	< 0.01							
Stool consistency	0.211	< 0.02		0.275	< 0.01				
Stool frequency	0.134	> 0.1		0.131	> 0.1		0.286	< 0.01	
Average Inter-item Correlation = 	0.265	< 0.01	
Day 3	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.566	< 0.01							
Stool consistency	0.318	< 0.01		0.191	< 0.05				
Stool frequency	0.223	< 0.02		0.189	< 0.05		0.152	< 0.1	
Average Inter-item Correlation = 	0.273	< 0.01	
Week 1	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.766	< 0.01							
Stool consistency	0.488	< 0.01		0.482	< 0.01				
Stool frequency	0.353	< 0.01		0.368	< 0.01		0.468	< 0.01	
Average Inter-item Correlation = 	0.486	< 0.01	
Week 4	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.914	< 0.01							
Stool consistency	0.680	< 0.01		0.610	< 0.01				
Stool frequency	0.542	< 0.01		0.520	< 0.01		0.597	< 0.01	
Average Inter-item Correlation = 	0.644	< 0.01	
Post-treatment
Day 1	Pain	 	 	Pain freq	 	 	Stool consist	 	 
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.854	< 0.01							
Stool consistency	0.661	< 0.01		0.592	< 0.01				
Stool frequency	0.552	< 0.01		0.446	< 0.01		0.595	< 0.01	
Average Inter-item Correlation = 	0.617	< 0.01	
Day 2	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.813	< 0.01							
Stool consistency	0.729	< 0.01		0.612	< 0.01				
Stool frequency	0.625	< 0.01		0.527	< 0.01		0.710	< 0.01	
Average Inter-item Correlation = 	0.669	< 0.01	
Day 3	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.807	< 0.01							
Stool consistency	0.667	< 0.01		0.620	< 0.01				
Stool frequency	0.582	< 0.01		0.529	< 0.01		0.678	< 0.01	
Average Inter-item Correlation = 	0.647	< 0.01	
Week 4	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.796	< 0.01							
Stool consistency	0.645	< 0.01		0.541	< 0.01				
Stool frequency	0.594	< 0.01		0.444	< 0.01		0.651	< 0.01	
Average Inter-item Correlation = 	0.612	< 0.01	
Week 9	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.760	< 0.01							
Stool consistency	0.641	< 0.01		0.557	< 0.01				
Stool frequency	0.521	< 0.01		0.480	< 0.01		0.686	< 0.01	
Average Inter-item Correlation = 	0.608	< 0.01	
Week 17	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.753	< 0.01							
Stool consistency	0.643	< 0.01		0.551	< 0.01				
Stool frequency	0.553	< 0.01		0.552	< 0.01		0.661	< 0.01	
Average Inter-item Correlation = 	0.619	< 0.01	
Week 25	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.723	< 0.01							
Stool consistency	0.659	< 0.01		0.514	< 0.01				
Stool frequency	0.537	< 0.01		0.446	< 0.01		0.611	< 0.01	
Average Inter-item Correlation = 	0.582	< 0.01	
Week 33	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.735	< 0.01							
Stool consistency	0.596	< 0.01		0.452	< 0.01				
Stool frequency	0.515	< 0.01		0.446	< 0.01		0.637	< 0.01	
Average Inter-item Correlation = 	0.563	< 0.01	
Week 45	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.704	< 0.01							
Stool consistency	0.592	< 0.01		0.495	< 0.01				
Stool frequency	0.466	< 0.01		0.419	< 0.01		0.634	< 0.01	
Average Inter-item Correlation = 	0.552	< 0.01	
Week 57	Pain	 	 	Pain freq	 	 	Stool consist	 	
	r	P value 		r	P value 		r	P value 	
Pain frequency	0.716	< 0.01							
Stool consistency	0.561	< 0.01		0.511	< 0.01				
Stool frequency	0.494	< 0.01		0.451	< 0.01		0.633	< 0.01	
Average Inter-item Correlation = 	0.561	< 0.01	








Day 1	68 (51.5%)		111 (84.1%)		< 0.001		
Day 2	65 (49.2%)		107 (81.1%)		< 0.001		
Day 3	58 (43.9%)		103 (78.0%)		< 0.001		
Week 1	55 (41.7%)		88 (67.4%)		< 0.001		
Week 4	49 (37.1%)		87 (65.9%)		< 0.001		
Post-treatment
Day 1	47 (35.6%)		90 (68.2%)		< 0.001		
Day 2	47 (35.6%)		92 (69.7%)		< 0.001		
Day 3	50 (37.9%)		88 (66.7%)		< 0.001		
Week 4	58 (43.9%)		77 (58.3%)		< 0.05		
Week 9	54 (40.9%)		75 (56.8%)		< 0.01		
Week 17	61 (46.2%)		75 (56.8%)		> 0.05		136 (51.5%)
Week 25	63 (47.7%)		78 (59.1%)		> 0.05		141 (53.4%)
Week 33	68 (51.5%)		81 (61.4%)		> 0.05		149 (56.4%)
Week 45	66 (50.0%)		79 (59.8%)		> 0.05		145 (54.9%)
Week 57	68 (51.5%)	 	77 (58.3%)	 	> 0.05	 	145 (54.9%)
 Notes: IBS symptoms were defined as pain scale ≥ 3 and Bristol stool scale ≥ 5. N = 132

Table S10.	Average Inter-item Correlation (r∑) analysis between global overall symptom scales and symptomatic endpoints during / post- treatment (ITT)
 	Pain	 	Stool consistency	 	Pain frequency	 	Stool frequency	 	 Average (r∑) 
	r	P value 		r	P value 		r	P value 		r	P value 		r	P value 

Day 1	0.301	< 0.01		0.392	< 0.01		0.201	< 0.05		0.179	> 0.1		0.268	< 0.02
Day 2	0.367	< 0.01		0.342	< 0.01		0.310	< 0.01		0.226	< 0.01		0.311	< 0.01
Day 3	0.643	< 0.01		0.425	< 0.01		0.400	< 0.01		0.259	< 0.01		0.432	< 0.01
Week 1	0.646	< 0.01		0.608	< 0.01		0.596	< 0.01		0.389	< 0.01		0.560	< 0.001
Week 4	0.819	< 0.01		0.664	< 0.01		0.815	< 0.01		0.597	< 0.01		0.724	< 0.01

Day 1	0.787	< 0.01		0.573	< 0.01		0.696	< 0.01		0.413	< 0.01		0.618	< 0.01
Day 2	0.800	< 0.01		0.639	< 0.01		0.751	< 0.01		0.513	< 0.01		0.676	< 0.01
Day 3	0.818	< 0.01		0.723	< 0.01		0.744	< 0.01		0.569	< 0.01		0.714	< 0.01
Week 4	0.858	< 0.01		0.690	< 0.01		0.766	< 0.01		0.619	< 0.01		0.733	< 0.01
Week 9	0.803	< 0.01		0.702	< 0.01		0.695	< 0.01		0.543	< 0.01		0.686	< 0.01
Week 17	0.824	< 0.01		0.696	< 0.01		0.700	< 0.01		0.616	< 0.01		0.709	< 0.01
Week 25	0.750	< 0.01		0.667	< 0.01		0.582	< 0.01		0.497	< 0.01		0.624	< 0.01
Week 33	0.713	< 0.01		0.641	< 0.01		0.562	< 0.01		0.587	< 0.01		0.626	< 0.01
Week 45	0.768	< 0.01		0.635	< 0.01		0.607	< 0.01		0.546	< 0.01		0.639	< 0.01
Week 57	0.733	< 0.01	 	0.647	< 0.01	 	0.622	< 0.01	 	0.627	< 0.01	 	0.657	< 0.01






































































^1	  ITT = intention-to-treat population; PP = per-protocol population.
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